The Impact of 524B(b)(2) on Medical Device Cybersecurity

Section 524B(b)(2) changed medical device cybersecurity from guidance-driven good practice into a statutory requirement. If a product meets the definition of a cyber device, manufacturers now need to show the FDA that cybersecurity is built into design, maintenance, and update processes across the device lifecycle.

Key Takeaways

• 524B(b)(2) makes cybersecurity a statutory requirement for cyber devices.
• Manufacturers must integrate security into design, development, and maintenance.
• Evidence of risk-based controls and vulnerability management is essential.
• Devices need ongoing support, including patching and updates.
• The FDA expects operationalized security practices, not just policies.
• Makers must demonstrate how security decisions are made and sustained.

Table of Contents

• Key Takeaways
• What 524B(b)(2) Requires
• Why 524B(b)(2) Matters for Medical Device Cybersecurity
• What It Means for Device Manufacturers
• What It Means for Healthcare Providers
• Where This Is Headed

What 524B(b)(2) Requires

524B(b)(2) sits within the FD&C Act’s cyber device requirements and focuses on process, not checkbox paperwork. The law expects manufacturers to design, develop, and maintain processes that provide reasonable assurance that a device and related systems are cybersecure.

At a practical level, that means manufacturers need to do more than claim they take security seriously. They need evidence. They need risk-based design controls. They need a plan to identify vulnerabilities, reduce exploitability, and make patches and updates available on an ongoing basis.

The statutory language in 524B(b)(2) also lines up with what the FDA has been signaling for years: cybersecurity belongs in product development, validation, release management, and postmarket support. It is not something to bolt on at the end of a submission.

Core expectations for manufacturers

For most device manufacturers, 524B(b)(2) translates into a few non-negotiable expectations:

• Security requirements must be defined during design and development.
• Risk analysis must address cybersecurity threats, not just safety hazards in isolation.
• Manufacturers need repeatable processes for vulnerability intake, triage, remediation, and disclosure.
• Devices must be supportable in the field, including the ability to deliver patches and updates as appropriate.
• Submission materials need to show how these processes work in practice, not just that a policy exists.

That last point matters. The FDA is not asking for checklist theater. Reviewers want to see how security decisions were made, how risks were evaluated, and how the manufacturer will maintain the device after it ships. That is a much higher bar than a generic statement about “industry best practices” or a comprehensive risk assessments to identify vulnerabilities claim with no operational backing.

Why 524B(b)(2) Matters for Medical Device Cybersecurity

Connected devices create a larger attack surface. They also create a direct path from technical weakness to patient harm, operational disruption, privacy exposure, or all three at once. 524B(b)(2) matters because it forces sponsors to treat those risks as product risks.

That shift has consequences. Security architecture, authentication, logging, update mechanisms, software bill of materials management, and vulnerability handling are no longer side issues for an engineering team to address later. They affect whether a submission is ready and whether a device can be sustained in the market.

The requirement also raises the floor for the industry. Manufacturers that already built security into their quality system and development lifecycle are in a stronger position. Those that relied on minimal documentation or outsourced security thinking to a late-stage test report now have to close real gaps.

What It Means for Device Manufacturers

For manufacturers, 524B(b)(2) changes both premarket preparation and postmarket obligations.

On the premarket side, teams need better alignment between engineering, quality, regulatory, and security. Threat modeling, security requirements, architecture decisions, testing evidence, and update planning all need to connect. If they do not, the submission will show the seams.

On the postmarket side, the device must remain supportable. A manufacturer needs a credible way to monitor for vulnerabilities, assess impact, develop remediations, and communicate changes. Security does not end at clearance or approval. The law makes that explicit.

See also: De Novo Cybersecurity Requirements: What the FDA Expects, FDA Cybersecurity Major vs Minor Deficiency: How Reviewers Grade Findings, and FDA Cybersecurity Deficiencies in PMA Submissions: AI Requests, Major Deficiencies, and Complete Response Letters.

There is also a business reality here. Manufacturers that can demonstrate mature cybersecurity processes are easier for health systems to trust. Procurement teams, security teams, and clinical engineering groups increasingly ask hard questions about supportability, patching, third-party software, and coordinated vulnerability disclosure. 524B(b)(2) pushes manufacturers toward answers that stand up under scrutiny.

What It Means for Healthcare Providers

The statute is directed at manufacturers, but providers feel the impact immediately. Hospitals and health systems depend on vendors to deliver devices that can be deployed, monitored, and maintained without creating unmanaged cyber risk.

That means providers should expect clearer security documentation, better-defined patching processes, and more realistic conversations about asset inventory, network segmentation, update timing, and end-of-support planning. If a manufacturer cannot explain how the device is maintained securely, providers inherit the operational risk.

Providers still have work to do on their side. They need to validate device inventories, understand which assets are cyber devices, coordinate patch windows, and build incident response procedures that account for clinical operations. But 524B(b)(2) shifts more accountability back where it belongs: onto the manufacturer to deliver and support a cybersecure product.

Where This Is Headed

524B(b)(2) is not the end state. It is the baseline. The FDA will continue refining how it evaluates cybersecurity evidence through guidance, review practice, and feedback to sponsors. Expectations around secure update capability, coordinated vulnerability disclosure, SBOM quality, and postmarket monitoring will keep maturing.

Manufacturers should plan accordingly. The winning approach is not to produce prettier documentation right before submission. It is to build a development and maintenance system that generates defensible evidence as a byproduct of doing the work correctly.

That is the real impact of 524B(b)(2). It forces cybersecurity into the operating model of medical device companies. The organizations that adapt will move faster, defend their design choices more effectively, and ship products that are safer to connect and easier to maintain.

As medical device cybersecurity expectations tighten, manufacturers need partners who understand both the technical work and the FDA implications. Blue Goat Cyber helps device companies test products, strengthen secure development practices, and prepare evidence that holds up under regulatory review. Contact us today for cybersecurity help if you need to close gaps before submission or improve postmarket readiness.

Check out our medical device cybersecurity premarket submission FDA compliance package.

How Blue Goat approaches this

Blue Goat Cyber assists medical device manufacturers in navigating the complexities of 524B(b)(2) and establishing defensible cybersecurity programs. Our approach focuses on developing tailored security architectures, implementing practical risk management frameworks, and operationalizing secure development lifecycles. We guide clients through premarket submissions, ensuring their devices meet statutory requirements and the expectations set forth in the FDA Cybersecurity in Medical Devices Final Guidance dated February 3, 2026. Our team, comprised of certified professionals (CISSP, OSCP, ex-military red team), brings deep technical expertise and regulatory understanding to each engagement. We help embed essential security principles from design conception through postmarket support. If the FDA raises cybersecurity deficiencies after our submission, we resolve them at no additional cost. Learn more at bluegoatcyber.com/services/fda-premarket-cybersecurity-services.

FAQ

What is the primary impact of 524B(b)(2) on medical device manufacturers?

The primary impact is that cybersecurity is now a statutory requirement for cyber devices, demanding manufacturers provide evidence of integrated security processes throughout the device lifecycle to the FDA. It shifts the focus from voluntary guidelines to mandatory compliance.

How does 524B(b)(2) affect medical device design and development?

Manufacturers must define security requirements early in design, conduct risk analyses that include cybersecurity threats, and implement repeatable processes for vulnerability handling. Security architecture, authentication, and update mechanisms are no longer secondary considerations but integral to product development.

Does 524B(b)(2) change postmarket obligations for medical devices?

Yes, 524B(b)(2) explicitly mandates that devices remain supportable postmarket. Manufacturers need credible processes for monitoring vulnerabilities, assessing their impact, developing remediations, and communicating changes to ensure long-term device security and functionality.

What evidence does the FDA expect under 524B(b)(2)?

The FDA expects evidence demonstrating how security decisions were made, how risks were evaluated, and how the manufacturer will maintain the device throughout its lifecycle. This goes beyond generic policy statements, requiring proof of operationalized security aspects.

How does this regulation benefit healthcare providers?

Healthcare providers can expect clearer security documentation, better-defined patching processes, and more realistic conversations about device supportability. This shifts more accountability to manufacturers for delivering and supporting cybersecure products, reducing operational risk for providers.

Related: The Rising Tide of Cyber Threats in Medical Devices: Understanding the Risks

About the author

Christian Espinosa, CISSP, Founder, Blue Goat Cyber. Christian leads a team focused exclusively on medical device cybersecurity for FDA premarket submissions and postmarket compliance. Read more about Christian.